Seer Files ITC Complaint Against Nanomics

Market Reality Check

Price: $1.9300 Vol: Volume 112,921 vs 20-day ...

low vol

$1.9300 Last Close

Volume Volume 112,921 vs 20-day average 367,780 (relative volume 0.31x) indicates subdued trading ahead of this IP update. low

Technical Shares trade at $1.93, slightly below the $1.96 200-day MA and about 19.92% below the $2.41 52-week high.

Peers on Argus

SEER gained 2.12% while peers showed mixed moves: IOBT up 68.42%, ADAG and FBIO ...

1 Up 1 Down

SEER gained 2.12% while peers showed mixed moves: IOBT up 68.42%, ADAG and FBIO modestly positive, CGEN and KALA negative. Momentum scanner shows only one peer moving up and one down, supporting a stock-specific reaction to this IP enforcement news rather than a broad sector move.

Historical Context

5 past events · Latest: May 26 (Positive)

Pattern 5 events

Date	Event	Sentiment	Move	Catalyst
May 26	AI/proteomics showcase	Positive	+1.1%	Planned showcase of AI-driven screening and next-gen proteomics tools at ASMS 2026.
May 21	Bid rejection	Positive	+1.1%	Board unanimously rejected Radoff-JEC offer at $2.40 plus CVR as undervaluing Seer.
May 14	Acquisition proposal	Positive	-1.1%	Radoff-JEC Group submitted third non-binding proposal to acquire Seer.
May 13	Q1 2026 earnings	Negative	-1.1%	Reported revenue decline, ongoing net loss, but reaffirmed 2026 revenue outlook.
May 13	Patent lawsuit	Positive	-2.8%	Filed patent infringement lawsuit against Nanomics to protect IP position.

Pattern Detected

Recent news often sees modest price reactions, with takeover and litigation headlines sometimes showing divergence between perceived positive catalysts and near-term price moves.

Recent Company History

Over the past month, Seer has reported Q1 2026 results, reaffirmed $16–$18M revenue guidance, and highlighted strong cash of about $220M. It faced an active contest from the Radoff-JEC Group, including a rejected $2.40-per-share proposal and related proxy filings. The company also filed a patent infringement lawsuit against Nanomics. Today’s ITC complaint extends that IP protection effort and builds directly on the May 12 district court case.

Market Pulse Summary

This announcement details an ITC complaint that builds on Seer’s May 12, 2026 patent infringement la...

Analysis

This announcement details an ITC complaint that builds on Seer’s May 12, 2026 patent infringement lawsuit against Nanomics, seeking an exclusion order on Proteonano kits and workstations. It underscores the company’s focus on protecting nanoparticle protein enrichment IP supporting deep, unbiased proteomics. In context with recent earnings, cash disclosures, and an active proxy contest, investors may watch how this case progresses and interacts with broader strategic and governance developments.

Key Terms

international trade commission, patent infringement, intellectual property, proteomics

4 terms

international trade commission regulatory

"filed a complaint at the United States International Trade Commission (ITC) against Nanomics"

A government body that acts like a referee for cross-border commerce, reviewing complaints about unfair practices, banned imports, tariffs or patent violations and issuing rulings or penalties. Its decisions can quickly change which foreign products can be sold, add costs through duties or block imports entirely, so investors watch rulings for sudden impacts on a company’s sales, supply chains, profit margins and competitive position.

patent infringement regulatory

"The ITC complaint builds on the patent infringement suit filed in federal district court"

Patent infringement occurs when someone makes, uses, sells or imports a product or process that is covered by another party’s patent without permission — like copying a chef’s secret recipe and selling the dish without consent. For investors it matters because alleged infringement can trigger costly lawsuits, damage awards, sales bans or forced licensing, any of which can reduce revenue, increase expenses and hurt a company’s stock value.

intellectual property regulatory

"which protect Seer's intellectual property in the field of nanoparticle protein enrichment"

Intellectual property are legal rights that protect creations of the mind—such as inventions, brand names, designs, software, or secret formulas—giving the owner control over who can use, copy or sell them. For investors, IP is like owning a blueprint or recipe: it can generate steady income through exclusive sales or licensing, boost a company’s competitive edge and valuation, and also create costs or risks if rights must be defended or challenged in court.

proteomics medical

"deep, unbiased proteomic insights, today announced that it has filed a complaint"

Proteomics is the large-scale study of all the proteins produced by a cell, tissue or organism, like taking a full inventory and watching how the workforce and machines inside a factory behave. For investors, proteomics matters because it helps identify drug targets, disease indicators and responses to treatments—information that can speed development, reduce risk, guide partnerships and reveal new commercial opportunities in biotech and diagnostics.

AI-generated analysis. Not financial advice.

Seeks Exclusion Order Barring Importation of Infringing Proteonano Kits and Workstations

REDWOOD CITY, Calif., May 29, 2026 (GLOBE NEWSWIRE) -- Seer, Inc. (Nasdaq: SEER), a pioneer and trusted partner for deep, unbiased proteomic insights, today announced that it has filed a complaint at the United States International Trade Commission (ITC) against Nanomics Biotechnology Co., Ltd. The Brigham and Women's Hospital has joined the ITC complaint as well.

The ITC complaint builds on the patent infringement suit filed in federal district court on May 12, 2026, and is based on Nanomics' infringement of U.S. Patent Nos. 11,435,360, 11,630,112, 12,050,222, 12,228,566, and 12,590,948, which protect Seer's intellectual property in the field of nanoparticle protein enrichment. Seer's ITC complaint seeks institution of an investigation into Nanomics' importation and sale of its Proteonano kits and workstations, and an exclusion order barring those products from entering the United States.

"Seer pioneered the technology and advanced the science that makes it possible to pursue deep, unbiased proteomics at scale, catalyzing large data sets that will drive AI-enabled biological discoveries. We have an obligation to ensure that this technology delivers the most robust and reproducible data for our customers," said Omid Farokhzad, Chair and Chief Executive Officer of Seer. "Filing this ITC complaint, alongside our district court action, reflects our resolve to use every available avenue to protect our technology, innovations, and product integrity that have defined this field and that our customers rely on every day."

About Seer, Inc.
Seer, Inc. (Nasdaq: SEER) sets the standard in deep, unbiased proteomics, delivering insights with scale, speed, precision, and reproducibility previously unattainable. Seer’s Proteograph® Product Suite integrates proprietary engineered nanoparticles, streamlined automation instrumentation, optimized consumables, and advanced analytical software to overcome the throughput and complexity limitations of traditional proteomic methods. Seer’s products are for research use only and are not intended for diagnostic procedures. For more information, visit www.seer.bio

Forward-Looking Statements
This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. Such forward-looking statements are based on Seer’s beliefs and assumptions and on information currently available to it on the date of this press release. Forward-looking statements may involve known and unknown risks, uncertainties and other factors that may cause Seer’s actual results, performance, or achievements to be materially different from those expressed or implied by the forward-looking statements. These statements include but are not limited to statements regarding Seer’s proprietary technology and products and any third-party infringement thereof. These and other risks are described more fully in Seer’s filings with the Securities and Exchange Commission (“SEC”) and other documents that Seer subsequently files with the SEC from time to time. Except to the extent required by law, Seer undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made.

Media Contact:
Patrick Schmidt
pr@seer.bio

Investor Contact:
Marissa Bych
investor@seer.bio